GAINESVILLE, FL – (Businesswire) – March 23, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the Safety Review Committee for its Phase I trial in NPC has determined that Trappsol® Cyclo™ has an acceptable safety profile in patients with Niemann-Pick Disease Type C1...Read more
This webinar has been organised by patient organisations working in the field of Inherited Metabolic Diseases (IMD). It is open to patients and families affected by IMD and it aims to address questions raised by the outbreak of novel coronavirus (COVID-19)...Read more
Toni Mathieson, NPUK Chief Executive: I wanted to take this opportunity to let our patients, families and supporters know how NPUK is responding to the coronavirus (COVID-19) pandemic...Read more
This is an open call to all patients and families affected by metabolic diseases to submit questions regarding the outbreak of novel coronavirus (COVID-19).
Your questions will be addressed by an expert panel, including Dr Robin Lachmann and Dr Elaine Murphy (Charles Dent Metabolic Unit, National Hospital for Neurology, London).
Information about how to register will follow. Please submit your questions by noon tomorrow (Wednesday 18th March) to: email@example.comRead more
This is an updated version of the statement shared last week (13/3) regarding coronavirus (COV-19) containing new information.Read more